Technology
Health
Biotechnology

Pfenex

$5.25
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.15 (2.94%) Today
+$0.15 (2.94%) Today

Why Robinhood?

You can buy or sell Pfenex and other stocks, options, ETFs, and crypto commission-free!

About

Pfenex Inc., also called Pfenex, is a clinical-stage biotechnology company, which engages in the research, development, and commercialization of pharmaceutical products. Its portfolio includes biosimilars and vaccines. Read More The company was founded on November 19, 2009 and is headquartered in San Diego, CA.

Employees
71
Headquarters
San Diego, California
Founded
2009
Market Cap
160.48M
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
139.25K
High Today
$5.25
Low Today
$5.14
Open Price
$5.14
Volume
10.90K
52 Week High
$8.42
52 Week Low
$3.13

Collections

Technology
Health
Biotechnology
Medical
Pharmaceutical
2014 IPO
US
North America

News

Seeking AlphaMar 11

Pfenex's (PFNX) CEO Eef Schimmelpennink on Q4 2018 Results - Earnings Call Transcript

Pfenex Inc. (NYSEMKT:PFNX) Q4 2018 Earnings Conference Call March 11, 2019 4:30 PM ET Company Participants Eef Schimmelpennink - President and CEO Susan Knudson - CFO Conference Call Participants Jason Butler - JMP Securities Andy Hsieh - William Blair Operator Greetings, ladies and gentlemen, and welcome to the Pfenex Fourth Quarter and Fiscal Year-end 2018 Results and Business Update Cal. A Brief question-and-answer session will follow the formal presentation. As a reminder, this conference is bei...

37
BenzingaMar 11

Pfenex (NYSE:PFNX) - Q4 Earnings Outlook For Pfenex

Pfenex (NYSE: PFNX) releases its next round of earnings this Monday, Mar. 11. Get the latest predictions in Benzinga's essential guide to the company's Q4 earnings report. Earnings and Revenue Wall Street analysts see Pfenex reporting a loss of 35 cents per share on revenue of $4.4 million. In the same quarter last year, Pfenex announced EPS of 23 cents on revenue of $17.9 million. Revenue would have fallen 75.43 percent from the same quarter last year. The company's reported EPS has stacked up against a...

52
MarketBeatMar 9

Stock Price, News, & Analysis for Pfenex

Pfenex Inc., a clinical-stage biotechnology company, develops biosimilar therapeutics in the United States. The company's lead product candidates include PF708, a therapeutic equivalent candidate to Forteo (teriparatide) for the treatment of osteoporosis; and novel anthrax vaccine candidates, such as Px563L and RPA563 that are in Phase I study. It develops PF529, a biosimilar candidate to Neulasta; PF530, a biosimilar candidate to Betaseron; and hematology/oncology products, including PF743 and PF745. The c...

0

Earnings

-$0.56
-$0.30
-$0.03
$0.23
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.35 per share
Actual
-$0.22 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.